HUTCHMED (China) vs Nurix Therapeutics
HCM and NRIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCM and NRIX compare
Nurix Therapeutics grew revenue faster over the last twelve months (739% versus −13.0% for HUTCHMED (China)).
HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with 42.0% at Nurix Therapeutics.
Nurix Therapeutics scores higher on the StockData Score (15 against 5 for HUTCHMED (China)), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCM | NRIX |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.7B |
| Share price | $14.90 | $15.48 |
| Change, 1 year | −2.5% | 27.2% |
| Change, 5 years | −51.5% | −50.6% |
| Beta (5Y) | 0.97 | 1.46 |
| Employees | 109 | 317 |
| StockData Score | ||
| Total score | 5 | 15 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 3 | 3 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 6.7× |
| P/S | – | 2.4× |
| P/B | – | 1.7× |
| EV/EBITDA | – | 2.0× |
| P/FCF | – | 4.6× |
| FCF yield | – | 21.9% |
| Fair value | – | $57.66 |
| Margin of safety | – | 73.2% |
| Growth | ||
| Revenue growth (TTM) | −13.0% | 739% (better) |
| Revenue growth, 5Y average | 19.2% | 36.3% (better) |
| Net income growth (TTM) | 1111% | – |
| EPS growth (TTM) | 1200% | – |
| Profitability | ||
| Gross margin | 38.7% | – |
| Operating margin | −7.1% | 41.3% (better) |
| Net margin | 83.3% (better) | 42.0% |
| FCF margin | −14.4% | 52.7% (better) |
| Return on equity | 36.7% | 44.0% (better) |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.00 |
| Interest coverage | −13.7× | – |
| Current ratio | 5.64 | 8.44 (better) |
| Altman Z-score | – | 6.10 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −1.1% |
| Shareholder yield | – | −1.1% |
| Ownership | ||
| Held by institutions | 0.51% | 107% |
| Held by insiders | 0.44% | 3.2% |
| Insider net buying, 12 months | – | −$5.2M |
| Short interest, % of float | – | 17.9% |
Go deeper
- HCM stock overview
- HCM income statement
- HCM valuation and score
- NRIX stock overview
- NRIX income statement
- NRIX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.